Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mivavotinib - Calithera Biosciences

Next Previous
X
Search
Drug Profile

Mivavotinib - Calithera Biosciences

Alternative Names: CB-659; TAK-659

Latest Information Update: 11 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium
  • Developer Children's Cancer Research Institute; National Cancer Institute (USA); Northwestern University; RTI International; Takeda Oncology
  • Class Amines; Antineoplastics; Cyclohexanes; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Lymphoid leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 04 Apr 2023 Calithera Biosciences terminates a phase II trial in diffuse large B-Cell lymphoma in the US as per the sponsors decision (NCT05319028)
  • 09 Jan 2023 Discontinued - Phase-I for Diffuse large B cell lymphoma (Combination therapy) in USA (PO)
  • 09 Jan 2023 Discontinued - Phase-I for Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top